Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns

Bibliography

• Basavaraj S, Betageri GV. Can formulation and drug delivery reduce attrition during drug discovery and development – review of feasibility, benefits and challenges. Acta Pharmaceutica Sinica B 2014;4:3-17
   PubMed Web of Science ®Google Scholar
• Tilborg A, Norberg B, Wouters J. Pharmaceutical salts and cocrystals involving amino acids: a brief structural overview of the state-of-art. Eur J Med Chem 2014;74:411-26
   PubMed Web of Science ®Google Scholar
• Peng D, Xu Z, Yang C, et al. Metabolically stabilized structural modification on the helix B surface peptide of erythropoietin. Design, synthesis and improved renoprotective effect. Scientia Sinica Chimica 2013;43:1033-40
   Google Scholar
• Zhao SQ, Zhang Y, Tian H, et al. Extending the serum half-life of G-CSF via fusion with the domain III of human serum albumin. Biomed Res Int 2013;2013:107238
   Google Scholar
• Insaidoo FK, Borbulevych OY, Hossain M, et al. Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design. J Biol Chem 2011;286:40163-73
   PubMed Web of Science ®Google Scholar
• Huang S, Fang R, Xu J, et al. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug. J Drug Target 2011;19:487-96
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36-48
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8
   PubMed Web of Science ®Google Scholar
• Abuchowski A, van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252:3578-81
   PubMed Web of Science ®Google Scholar
• Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6
   PubMed Web of Science ®Google Scholar
• Ritika Harikumar SL, Aggarwal G. Formulation tactics for the delivery of poorly soluble drugs. Int J PharmTech Res 2012;4:914-23
   Google Scholar
• Deavall DG, Martin EA, Horner JM, et al. Drug-induced oxidative stress and toxicity. J Toxicol 2012;2012:645460
   PubMedGoogle Scholar
• Li W, Zhan P, De Clercq E, et al. Current drug research on PEGylation with small molecular agents. Prog Polym Sci 2013;38:421-44
   Web of Science ®Google Scholar
• Henning T. Polyethylene glycols (PEGs) and the pharmaceutical industry. Fine Spec Perform Chemicals 2002;7:57-9
   Google Scholar
• He Y, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 1998;87:626-33
   PubMed Web of Science ®Google Scholar
• Donovan MD, Flynn GL, Amidon GL. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res 1990;7:863-8
   PubMed Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 2012;13:105-19
   PubMed Web of Science ®Google Scholar
• Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007;35:9-16
   PubMed Web of Science ®Google Scholar
• Herold DA, Keil K, Bruns DE. Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem Pharmacol 1989;38:73-6
   PubMed Web of Science ®Google Scholar
• Friman S, Egestad B, Sjovall J, et al. Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat. J Hepatol 1993;17:48-55
   PubMed Web of Science ®Google Scholar
• Guiotto A, Canevari M, Pozzobon M, et al. Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg Med Chem 2004;12:5031-7
   PubMed Web of Science ®Google Scholar
• Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113-28
   PubMed Web of Science ®Google Scholar
• Webster R, Elliott V, Park BK, et al. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese F, editor. PEGylated protein drugs: basic science and clinical applications. Birkhäuser; Basel: 2009. p. 127-46
   Google Scholar
• Renukuntla J, Vadlapudi AD, Patel A, et al. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 2013;447:75-93
   PubMed Web of Science ®Google Scholar
• Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release 2001;72:217-24
   PubMed Web of Science ®Google Scholar
• Lee S, Youn YS, Lee SH, et al. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 2006;49:1608-11
   PubMed Web of Science ®Google Scholar
• Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68
   PubMed Web of Science ®Google Scholar
• Koussoroplis SJ, Heywood S, Uyttenhove C, et al. Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments. Int J Pharm 2013;454:107-15
   PubMedGoogle Scholar
• Koussoroplis SJ, Paulissen G, Tyteca D, et al. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J Control Release 2014;187C:91-100
   Google Scholar
• Zhai Y, Zhao Y, Lei J, et al. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J Biotechnol 2009;142:259-66
   PubMed Web of Science ®Google Scholar
• Veronese MF, Caliceti P, Schiavon O. Branched and linear poly(Ethylene Glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J Bioact Compat Polym 1997;12:196-207
   Web of Science ®Google Scholar
• Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001;15:419-29
   PubMed Web of Science ®Google Scholar
• Foster GR. Pegylated interferons for the treatment of chronic hepatitis C pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010;70:147-65
   PubMed Web of Science ®Google Scholar
• Elliott VL, Edge GT, Phelan MM, et al. Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies. Mol Pharm 2012;9:1291-301
   PubMed Web of Science ®Google Scholar
• Mircera-EPAR. Available from: http://www.ema.europa.eu/ema/ [Last updated 19 June 2014]
   Google Scholar
• CIMZIA-EPAR. Available from: http://www.ema.europa.eu/ema/ [Last updated 01 March 2014]
   Google Scholar
• Krystexxa-EPAR. Available from: http://www.ema.europa.eu/ema/ [Last updated 01 February 2013]
   Google Scholar
• Bendele A, Seely J, Richey C, et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998;42:152-7
   PubMed Web of Science ®Google Scholar
• Cheng TL, Chuang KH, Chen BM, et al. Analytical measurement of PEGylated molecules. Bioconjug Chem 2012;23:881-99
   PubMed Web of Science ®Google Scholar
• Narang AS, Desai DS. Unique aspects of pharmaceutical development. In: Lu Y, Mahato RI, editors. Anticancer drug development. 2009. p. 49-92. Available from: http://www.springer.com/978-1-4419-0130-9
   Google Scholar
• Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010;49:6288-308
   PubMed Web of Science ®Google Scholar
• Glue P, Fang JWS, Rouzier-Panis R, et al. Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-67
   PubMed Web of Science ®Google Scholar
• Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195-202
   PubMed Web of Science ®Google Scholar
• Veronese FM, Schiavon O, Pasut G, et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 2005;16:775-84
   PubMed Web of Science ®Google Scholar
• Webster L, Blonsky ER, Matz P, et al. Efficacy, safety and pharmacokinetics of oral NKTR-118 in patients with opioid-induced constipation: results of a randomized, double-blind, placebo-controlled phase 2 study. Am J Gastroenterol 2009;104:S174
   Web of Science ®Google Scholar
• Greenwald RB, Pendri A, Bolikal D. Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. J Org Chem 1995;60:331-6
   Web of Science ®Google Scholar
• Banerjee SS, Aher N, Patil R, et al. Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. J Drug Deliv 2012;2012:103973
   PubMedGoogle Scholar
• Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009;61:1177-88
   PubMed Web of Science ®Google Scholar
• Scott LC, Yao JC, Benson AB III, et al. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 2009;63:363-70
   PubMed Web of Science ®Google Scholar
• Posey JA III, Saif MW, Carlisle R, et al. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res 2005;11:7866-71
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Aghajanian CA, Alberts DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:10-18
   PubMed Web of Science ®Google Scholar
• Atyabi F, Farkhondehfai A, Esmaeili F, et al. Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice. Acta Pharm 2009;59:133-44
   PubMed Web of Science ®Google Scholar
• Muppidi K, Wang J, Betageri G, et al. PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob Agents Chemother 2011;55:4537-42
   PubMed Web of Science ®Google Scholar
• Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007;28:869-76
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, McLeod VM, Kelly BD, et al. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Mol Pharm 2012;9:422-32
   PubMed Web of Science ®Google Scholar
• Lu J, Huang Y, Zhao W, et al. Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Mol Pharm 2013;10:2880-90
   PubMed Web of Science ®Google Scholar
• Hilmer SN, Cogger VC, Muller M, et al. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos 2004;32:794-9
   PubMed Web of Science ®Google Scholar
• Deenen MJ, Cats A, Beijnen JH, et al. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 2011;16:820-34
   PubMed Web of Science ®Google Scholar
• Deenen MJ, Cats A, Beijnen JH, et al. Part 3: pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist 2011;16:992-1005
   PubMed Web of Science ®Google Scholar
• Kling J. PEGylation of biologics: a multipurpose solution. BioProcess Int 2013;11:34-43
   Google Scholar
• Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev 1995;16:157-82
   Web of Science ®Google Scholar
• Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006;8:R12
   PubMed Web of Science ®Google Scholar
• Cheng TL, Chen BM, Chern JW, et al. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 2000;11:258-66
   PubMed Web of Science ®Google Scholar
• Zhang H, Wilson J, Zhang J, et al. Characterization of potential degradation products in a PEGylating reagent 20 kDa monomethoxy polyethylene glycol propionaldehyde by RP-HPLC, APCI-MS and NMR. J Pharm Biomed Anal 2014;89:221-6
   PubMed Web of Science ®Google Scholar
• Vllasaliu D, Fowler R, Stolnik S. PEGylated nanomedicines: recent progress and remaining concerns. Expert Opin Drug Deliv 2014;11:139-54
   PubMed Web of Science ®Google Scholar
• Toh M-R, Chiu GNC. Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian J Pharm Sci 2013;8:88-95
   Google Scholar
• Vos FY, Lesterhuis WJ, Bruggemann RJ, et al. Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment. Anticancer Drugs 2012;23:139-40
   PubMed Web of Science ®Google Scholar
• Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 2012;23(Suppl 10):x313-19
   PubMed Web of Science ®Google Scholar
• Laine GA, Hossain SM, Solis RT, et al. Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam. Ann Pharmacother 1995;29:1110-14
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36
   PubMed Web of Science ®Google Scholar
• Mross K, Niemann B, Massing U, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol 2004;54:514-24
   PubMed Web of Science ®Google Scholar
• Xu L, Wang W, Sheng YC, et al. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours. J Clin Pharm Ther 2010;35:593-601
   PubMed Web of Science ®Google Scholar
• Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011;354:116-23
   PubMed Web of Science ®Google Scholar
• Reddy PR, Venkateswarlu V. Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. J Drug Target 2005;13:543-53
   PubMed Web of Science ®Google Scholar
• Li S, Wang A, Jiang W, et al. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 2008;8:103
   PubMed Web of Science ®Google Scholar
• Madan J, Pandey RS, Jain V, et al. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine 2013;9:492-503
   PubMed Web of Science ®Google Scholar
• Gajbhiye V, Kumar PV, Sharma A, et al. Novel PEGylated PPI dendritic nanostructures for sustained delivery of anti-inflammatory agent. Curr Nanosci 2008;4:267-77
   Web of Science ®Google Scholar